DUBLIN – Idorsia Ltd. pressed the go button on its second pivotal program inside a month. The company has started enrolling patients in phase III trials of nemorexant (ACT-541468), a dual orexin receptor antagonist, for treating adult and elderly (ages 65 and older) patients with insomnia.